Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

Commentary on Twitter

NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine

Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard

— The BMJ (@bmj_latest) May 6, 2021